Treating the 'Silent' Liver Disease
As of April 17, 2026, the TGA has granted provisional approval for Wegovy to treat Metabolic Dysfunction-Associated Steatohepatitis (MASH), recognizing that organ protection is central to metabolic health.
Strategic Data Expansion 2026.4
The Fibrosis Reversal Data
Trials show significant reduction in liver fat and stabilization of scarring. [Image showing GLP-1 impact on liver cells] LSI keywords like 'steatohepatitis resolution' are trending in AU gastroenterology.
Hepatic Steatosis Index
Liver Fat Clearance
$$\Delta V_{fat} \propto \int [Semaglutide] \, dt$$
Strategic Advice: Australians with fatty liver now have a provisionally approved medical pathway beyond diet.